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We prospectively evaluated survival after NST dUCBT for poor
risk acute leukemia or lymphoma (excluding mantle cell) in patients
without a suitably matched related donor. Eligible were patients
aged # 70 years with adequate organ function (ejection fraction .
35%; lung function . 50% predicted; total bilirubin # 2.5 mg/dl,
liver enzymes\ 5  upper limit of normal; CrCl . 40 mL/min/
1.73m2), performance score (PS) $ 60, and . 3 months after prior
autologous transplant. The preparative regimen consisted of
fludarabine 40 mg/m2 IV days –6 to -2, cyclophosphamide 50 mg/
kg IV day -6, total body irradiation 200 cGy day –1 and immunosup-
pression with a calcineurin inhibitor and mycophenolate mofetil.
G-CSF started at day 11. All patients received dUCB grafts HLA-
matched 4-6/6 (A and B at antigen level, DRB1 allele level) to the
patient and to each other. Fifty-four patients were enrolled from
16 centers; 4 of 54 patients were excluded due to progressive disease
prior to dUCBT (n 5 3) and 1 withdrew consent. The median age
was 58 yrs (range, 16-69) and weight, 79kg (range, 46-119).
Thirty-six patients had acute leukemia (64% were in CR1) and 14
patients had lymphoma. Six patients (12%) had a prior autologous
transplant. The median infused combined nucleated cell dose was
4.2  107/kg (2.3-13.6). Fifty-three percent of the units were 4/6
and 39% were 5/6 HLA-matched to the recipient; 66% of patients
received at least one 4/6 HLA-matched unit. Most patients (80%)
had PS 90-100. The median follow-up of survivors was 364 days
(range, 154-381). The 6-month probability of overall survival was
72% (95%CI, 56-83%) and progression-free survival 63% (95%
CI, 48-76%). The cumulative incidence of treatment-relatedmortal-
ity at day-180 was 20% (95%CI, 8-31%) and relapse/progression,
14% (95%CI, 4-24%). Eighteen patients died and relapse/progres-
sion was the most common cause (N5 9). The cumulative incidence
of grade II-IV acute GVHD at day 56 is 36% (95%CI, 22-50%) and
grade III-IV 10% (95%CI, 2-19%) and chronic GVHD at 180 days
was 13% (5%CI, 3-24%). The cumulative incidence of neutrophil
recovery at day 56 was 94.0% (95%CI, 87-100.0%) at a median
time of 17 days (range, 6-45). Three patients had primary and 1 sec-
ondary graft failure. These data demonstrate that NST dUCBT is
safe, reproduced results from single centers in the multicenter set-
ting, and establishes the framework for randomized trials to study al-
ternative donor NST transplantation for hematologic malignancies.
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dentical BMT and GVHD prophylaxis incorporating high dose,
post-transplantation cyclophosphamide (Cy) for patients with poor
risk leukemia or lymphoma who lacked a HLA-matched related do-
nor. The trial enrolled 55 patients from 17 centers and 52 proceeded
to transplantation. Their median age was 51 years (range, 7-70); 32
were male, and 42, Caucasian. Diagnoses included acute myeloid
(10 in CR1, 13 in CR $ 2), acute lymphocytic (3 in CR1, 3 in CR
$ 2) biphenotypic/undifferentiated leukemia in CR (n5 3) and, re-
lapsed/chemosensitive Hodgkin (n 5 8), mantle cell (n 5 3), large
cell (n 5 8), and marginal zone B cell lymphoma (n 5 1). Thirty-
nine patients had performance status $ 90%, and 12 patients had
failed prior autologous SCT. Median donor age was 43 years and
the median mismatch, 5/10 HLA alleles in the graft-versus-host di-
rection and 4/10 alleles in the host-versus-graft direction. Patients
were conditioned with Cy (14.5 mg/kg IV, day -6, -5), fludarabine
(30 mg/m2 IV, day -6 to -2), total body irradiation (200 cGy, day
-1) followed by infusion of T-cell replete bonemarrow. GVHDpro-
phylaxis consisted of Cy 50 mg/kg IV on day13 and14, mycophe-
nolate mofetil, day 15 to 135, and tacrolimus, day 15 to 1180.
Filgrastim was given from day 15 until neutrophil recovery. The
median times to . 0.5  109/L neutrophils and platelets $ 20 
109/L, were 16 and 21 days, respectively. The median donor chime-
rism in marrow/blood at day 128 was 100% (range, 70-100%), and
T cell chimerism, 100%. One patient experienced primary graft fail-
ure and none, secondary graft failure. The day 156 incidence of
acute grade II GVHD was 31% (95% CI, 18-44%) and day 1180
chronic GVHD, 11% (95% CI, 1-22%). No patient experienced
grade III-IV acute GVHD.The day1180 incidences of relapse/pro-
gression and non-relapse mortality were 19% (95% CI, 7-32%) and
5% (95% CI, 0-13%), respectively. Ten patients experienced re-
lapse/progression and there were 13 deaths: relapse/progression (n
5 8); infection (n 5 2); graft failure (n 5 1); unknown (n 5 2).
With a median follow-up of surviving patients of 294 days (range
76-650), the 6-month probabilities of overall and event-free survival
are 82% (95% CI, 65-91%) and 75% (95% CI, 59-86%), respec-
tively. These results confirm nonmyeloablative, HLA-haploidentical
BMT is feasible, associated with low toxicity and these data may be
used to plan multi-center trials to identify the optimal alternative
donor.
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Adoptive transfer of CTLs can reconstitute antiviral immunity to
EBV, CMV and Adv in allogeneic hemopoietic stem cell transplant
(HSCT) recipients. However, the time taken to prepare patient-
specific products and the lack of virus-specific T-cells in cord blood
and seronegative donors restricts application. As part of the NHLBI
Specialized Centers for Cell-Based Therapy, we are evaluating in
a multicenter setting whether infusion of ‘‘off the shelf’’ closely
HLA-matched allogeneic CTLs (CHM-CTLs) will overcome this
limitation and prove feasible, safe and effective in HSCT recipients
with infection refractory to standard therapy. Using the NHLBI
Production Assistance for Cellular Therapies program, we manufac-
tured and tested. 30 multivirus lines, which were polyclonal, com-
prising CD41 (median 10%) and CD81 (median 83%) T-cells withS151
